BCMA plays a substantial role in developing the multiple myeloma cells and considers a proper target antigen by anti-BCMA antibody-drug conjugate (GSK2857916), bispecific T cell engager (BiTE) (AMG420), and CAR-T cell therapy [57, 58]. The gene discussed is TNFRSF17; the disease is AL amyloidosis.